

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-012024-000584

**Date:** 28<sup>th</sup> February 2024

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000.

**Request**

Q1. Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:

- Adalimumab - Humira
- Adalimumab Biosimilar
- Bimekizumab
- Certolizumab
- Infliximab
- Secukinumab
- Ustekinumab

Q2. In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were:

- Admitted as an inpatient
- Treated in A&E

Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:

- Tocilizumab – for any disease
- Tocilizumab for rheumatoid arthritis (RA) only
- Tocilizumab for giant cell arteritis (GCA) only

Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?

Q5. How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab?

Response

Q1. Could you please tell me how many patients were treated in the last 3 months for Hidradenitis Suppurativa (HS) with the following biologic drugs:	
a) Adalimumab - Humira	We cannot determine for what reason a patient was given a specific drug. We can say who was prescribed a certain drug but not why, therefore we are unable to answer this question.
b) Adalimumab Biosimilar	
c) Bimekizumab	
d) Certolizumab	
e) Infliximab	
f) Secukinumab	
g) Ustekinumab	
Q2. In the past 3 months, how many patients with a primary diagnosis of giant cell arteritis (ICD10 codes M31.5 or M31.6) were:	
Admitted as an inpatient	1
Treated in A&E	0
Q3. How many patients were treated by the rheumatology department in the past 3 months with the following:	
a) Tocilizumab – for any disease	<i>In the 3 months, Nov23-Jan24, 69 patients were treated by the rheumatology department with Tocilizumab (for any disease)</i>
b) Tocilizumab for rheumatoid arthritis (RA) only	We cannot determine for what reason a patient was given a specific drug. We can say who was prescribed a certain drug but not why, therefore we are unable to answer this question.
c) Tocilizumab for giant cell arteritis (GCA) only	
Q4. How many patients were treated by the ophthalmology department (for any disease) in the past 3 months with Tocilizumab?	<i>In the 3 months, Nov23-Jan24, 0 patients were treated by the ophthalmology department with Tocilizumab (for any disease)</i>
Q5. How many patients were treated in A&E in the past 3 months (for any disease) with Tocilizumab?	<i>In the 3 months, Nov23-Jan24, 0 patients were treated in A&amp;E with Tocilizumab (for any disease)</i>

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell’s Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire

**Ref:** FOI-012024-000584  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**